The joint venture aims to build the world's preeminent pediatric cancer center, increasing access to care and clinical trials. Collaborative operations will launch in early 2026, featuring a focus on new facilities with latest medical technology.
The University of Texas MD Anderson Cancer Center received nearly $23 million in CPRIT funding to advance cancer research, translational science, and clinical trials. The funding will support the recruitment of a first-time tenure-track faculty member and enhance the understanding of cancer biology.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
MD Anderson researchers have made significant breakthroughs in treating relapsed or refractory B-cell lymphoma with a novel allogeneic NK cell therapy. Additionally, targeted therapies have shown responses in HER2-mutant metastatic breast cancer, while a triplet combination of sitravatinib and immune checkpoint inhibitors has demonstra...
Be Well Beaumont aims to promote wellness and lower cancer risk among community members through cancer prevention education and tools. The initiative will focus on healthy eating, active living, sun safety, tobacco-free living, and preventive care.
Integrated care, combining medication and comprehensive counseling with tobacco treatment specialists, significantly improves quitting chances among smokers undergoing lung cancer screening. This randomized clinical trial found nearly two-fold improvement in quitting rates compared to other cessation methods.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Research from the University of Texas M. D. Anderson Cancer Center suggests that individuals with pre-existing cardiovascular disease are more likely to have advanced or metastatic breast cancer. The study found a 10% increased risk of CVD in patients with late-stage breast cancer compared to those with early-stage cancer.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers observed a 100% response rate on Phase Ib trial for patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis. Early intervention with ELA026 may provide meaningful clinical benefits for patients with few options.
The study presents strong overall responses with a triplet regimen including a novel menin inhibitor, achieving an 82% overall response rate in relapsed or refractory acute myeloid leukemia patients. The combination also demonstrated manageable side effects and significant clinical benefits, providing patients with improved treatment o...
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
The Phase Ib/II FELIX trial demonstrated a 76.6% response rate and 55.3% complete remission rate in 127 evaluable patients treated with obe-cel CAR T cell therapy. The median event-free survival was 11.9 months, and the overall survival was 15.6 months.
MD Anderson researchers have made significant advancements in treating chronic pain, myelodysplastic syndrome, and rare cancers. A novel treatment for chronic pain has been developed with reduced side effects, while targeted therapies like canakinumab show promise for personalized approaches.
The University of Texas MD Anderson Cancer Center has been awarded nearly $8 million in CPRIT funding to support lung and colorectal cancer screening programs, as well as faculty recruitment. The funding will enable the expansion of these programs to address high cancer incidence rates across Texas.
A new study from the University of Texas M. D. Anderson Cancer Center found that at least 3% of normal breast tissue cells in healthy women contain chromosome abnormalities associated with invasive breast cancer, which may guide future approaches to early detection.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
The institute will accelerate discovery and development of cell therapies, integrating MD Anderson's unique research expertise to advance impactful treatments. Key findings include successful CAR T cell therapy approvals and preclinical studies in solid tumors.
Tiffany Richards, a seasoned oncology nurse supervisor, receives the prestigious award for her exceptional patient care and dedication to clinical excellence. She joins an elite group of nursing professionals who have made significant contributions to advancing cancer treatment.
Jennifer Bickel, M.D., is named MD Anderson's inaugural Vice President and Chief Wellness Officer, focusing on employee well-being, professional fulfillment, and community resilience. She will lead the development of a groundbreaking wellness institute to foster engagement, psychological safety, and professional fulfillment.
Researchers at the University of Texas MD Anderson Cancer Center found that patients who quit smoking within six months of their cancer diagnosis saw improved longevity. Smoking cessation led to a 22%-26% reduction in cancer-related mortality and increased survival time from 2.1 years for smokers to 3.9 years for abstainers.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
Researchers at the University of Texas MD Anderson Cancer Center demonstrated that combining anti-PD-L1 immunotherapy with mutation-directed targeted therapy extended overall survival in patients with anaplastic thyroid carcinoma. The median OS across all cohorts was 19 months, compared to five months for historical data.
A study at the University of Texas M.D. Anderson Cancer Center found that adding CTLA-4 immune checkpoint inhibitors to durvalumab and chemotherapy improved overall response rates, progression-free survival, and overall survival for patients with metastatic non-squamous non-small cell lung cancer harboring STK11 and/or KEAP1 mutations.
Recent advances in radiation therapy have improved breast cancer outcomes with reduced side effects. Researchers at MD Anderson have demonstrated the benefits of hypofractionation in reducing lymphedema risk and improving treatment tolerance.
A Phase II trial found that a novel combination of decitabine, venetoclax, and ponatinib achieved complete remission in 80% of patients with advanced-phase chronic myeloid leukemia. The treatment showed promise even in patients with high-risk features and those who had received multiple prior therapies.
The Phase I/II trial of AZD8205, a topoisomerase 1 inhibitor ADC targeting B7-H4, demonstrated partial responses in ovarian, breast, and endometrial cancers. Notably, only two patients experienced severe toxicities, indicating a favorable safety profile.
A new study found that Americans from minority groups, current smokers, and those with lower education or income levels are more likely to be exposed to tobacco content on streaming services. The research revealed an estimated 12.4% of American adults were exposed to tobacco promotion on these platforms.
Natural killer cells engineered to express interleukin-21 demonstrate sustained antitumor activity against glioblastoma stem cell-like cells both in vitro and in vivo. IL-21 NK cells exhibit a stronger metabolic fitness than those expressing IL-15, leading to improved tumor control.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
Researchers at MD Anderson Cancer Center have identified a small molecule compound that restores physiological levels of telomerase reverse transcriptase (TERT), reducing cellular senescence and tissue inflammation. TERT restoration also spurred new neuron formation with improved memory and enhanced neuromuscular function.
Researchers from the University of Texas MD Anderson Cancer Center have engineered CAR NK cells with CD28 costimulation to improve antitumor activity and persistence. These cells demonstrated high cytotoxicity against CD70+ tumor cells in preclinical models, suggesting a promising approach for cancer therapy.
A Phase III trial led by the University of Texas M. D. Anderson Cancer Center found proton therapy to be non-inferior to traditional radiation therapy in treating head and neck cancer. The study revealed a significant reduction in malnutrition and feeding-tube dependency with proton therapy.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
Researchers found no significant improvement in overall survival after systemic therapy for patients with very advanced solid tumors. The study highlights the importance of providers focusing on palliative and supportive care options that have been demonstrated to improve quality of life and survival.
A Phase III study found that perioperative nivolumab plus chemotherapy significantly improved event-free survival in patients with resectable early-stage non-small cell lung cancer. The treatment also showed higher rates of pathological complete response and major pathological response compared to chemotherapy alone.
A new study from the University of Texas MD Anderson Cancer Center found that increasing treatment plan doses or altering regimens significantly improves cessation success for persistent smokers who previously tried to quit and failed. Varenicline was more effective than combined nicotine replacement therapy in aiding smokers to quit.
Cancer screening rates for breast, cervical, and colorectal cancer are significantly lower in US federally qualified health centers (FQHCs) compared to the general population. Screening use in FQHCs varies widely across states, with some achieving high rates while others fall below 35%.
Researchers at University of Texas M. D. Anderson Cancer Center have developed a new method for developing immunotherapy drugs using engineered peptides. The approach improved tumor control and prolonged survival in preclinical models of breast cancer.
Researchers from MD Anderson Cancer Center present early-phase clinical data demonstrating the efficacy of a new combination therapy, an antibody-drug conjugate, and molecularly selected patients in treating lymphoma and gastric cancers. The studies show promising initial results with improved response rates and overall survival.
A Phase I/II trial led by the University of Texas M. D. Anderson Cancer Center found saruparib effective against HRR-deficient breast cancers, demonstrating a favorable safety profile and high response rate. The drug's low dose-reduction rate compared to approved PARP inhibitors may enable longer treatment duration.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Scott Kopetz recognized for his development of novel therapies for BRAF-mutated colon cancer, while Elizabeth Travis awarded for her research on radiation effects on normal tissues. Their work has defined current practices in medical and radiation oncology.
Padmanee Sharma, a physician-scientist at MD Anderson, has been elected Fellow of the American Association for Cancer Research (AACR) Academy. Her groundbreaking research on immune checkpoint therapies has led to FDA approvals for treatments against metastatic bladder and kidney cancer.